The company most probably will raise cash by doing public offering any time soon. They have shelf ready to go. It's not something unusual.
PATH is a very good example of why you wrong. 2nd week of Jan will be a good time to start selling, not buying.
Since the stock is already trading at depressed price, I do think we will see new entries in the next two weeks ahead of the PDUFA date. However, I'm not expecting $1 any time soon. I think 0.55-0.6 is reasonable for the next two weeks, and 0.6-0.7 for mid-late Jan. It could reach $1 if the drug will be approved but I don't expect it to hold.
The two factors that have caused a depressing effect on IGXT were:
1. Warrants with an exercise price of $0.50 - expired at the end of August.
2. Overhang of a financing.
Now that these overhangs are out, I believe IGXT will be a run-up play in the next two weeks into their Feb PDUFA.
"Apple Patent For Connected Home Could Represent Long Term Big Opportunity"